Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$651.80 USD
-2.24 (-0.34%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $650.60 -1.20 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Regeneron Pharmaceuticals, Inc. has a market cap of $69.32B, which represents its share price of $654.04 multiplied by its outstanding shares number of 105.99M. As a large-cap company, REGN's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
REGN 651.80 -2.24(-0.34%)
Will REGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for REGN
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Other News for REGN
Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning
REGN forms Upper Bollinger Band Walk on October 31
Director’s Bold Move: Regeneron Stock Sale Shakes Up the Market!
Investor Michael Burry Warns Of Market Bubble
Upper Bollinger Band Walk appears for REGN after 0.17% move